MannKind and Rose Pharma Partner on Inhaled GLP-1

Danbury, Connecticut, USA, September 9, 2026

Companies Combine GLP-1 Drug and Inhalation Technology

Under the agreement, Rose Pharma will contribute its proprietary short-duration GLP-1 program, while MannKind will provide its Technosphere platform and expertise in inhaled pharmaceutical development and manufacturing. The collaboration is intended to leverage the companies’ complementary capabilities to develop a therapy that can potentially deliver a GLP-1 receptor agonist through the lungs rather than by injection. GLP-1 receptor agonists have become an important class of medicines for obesity and metabolic disease. However, many currently available therapies require subcutaneous administration and are designed to produce prolonged exposure. The companies believe an inhaled, rapid-acting and short-duration formulation could offer a different treatment profile, potentially giving patients and clinicians greater flexibility over when GLP-1 activity is delivered. The agreement represents another example of pharmaceutical developers exploring alternative drug-delivery technologies as demand for GLP-1-based therapies continues to expand. Oral, inhaled and other non-injectable approaches are being investigated to potentially improve convenience, treatment flexibility and patient acceptance.

Rapid-Acting GLP-1 Approach Targets Flexible Weight Management

The investigational Rose Pharma therapy is designed to provide rapid onset and relatively short duration of GLP-1 activity. This pharmacological profile is intended to distinguish the program from long-acting GLP-1 medicines that maintain drug exposure for days or weeks. GLP-1 signaling can influence several physiological processes associated with body weight, including appetite regulation, food intake and glucose metabolism. The therapeutic class has demonstrated substantial clinical effects on weight reduction, but individual patients may have different preferences and requirements regarding dosing frequency, route of administration and duration of drug exposure. An inhaled formulation could potentially provide an additional option if future clinical studies demonstrate that the delivery system can achieve appropriate pharmacokinetics, efficacy, safety and tolerability. However, these potential advantages remain hypotheses that must be validated through clinical development. MannKind’s Technosphere technology is designed to enable pulmonary delivery of pharmaceutical compounds. The platform uses engineered particles intended to facilitate rapid absorption through the lungs after inhalation. MannKind has previously applied the technology to inhaled medicines, providing the company with experience in pulmonary drug delivery and commercial-scale manufacturing. The new collaboration will therefore combine an established inhalation platform with a next-generation metabolic therapy concept.

Partnership Advances Non-Invasive GLP-1 Development

The agreement gives MannKind access to Rose Pharma’s GLP-1 program while providing Rose Pharma with MannKind’s development, regulatory, manufacturing and commercial expertise. The companies expect the collaboration to accelerate development of the inhaled candidate and establish a pathway toward clinical evaluation. The financial and development terms of the agreement include upfront and milestone-based payments, as well as potential commercial economics for the parties based on the future development and commercialization of the program. The agreement covers development and commercialization activities associated with the investigational therapy. For MannKind, the partnership expands its pipeline beyond existing inhaled products and demonstrates the potential application of its Technosphere platform to metabolic medicines. For Rose Pharma, collaboration with an established inhalation technology and manufacturing company provides additional resources to advance its GLP-1 program. Importantly, the inhaled GLP-1 candidate remains investigational. The agreement does not represent regulatory approval, and clinical development will be required to establish its safety and effectiveness for weight management. Future studies will need to determine appropriate dosing, pharmacokinetic characteristics, weight-management efficacy and tolerability. The partnership nevertheless highlights an important trend in pharmaceutical innovation: developers are increasingly exploring alternative routes of administration for established therapeutic mechanisms. If successful, an inhaled rapid-acting GLP-1 could potentially add greater flexibility to the growing weight-management treatment landscape. For cGxP.wire readers, the MannKind-Rose Pharma collaboration is significant because it combines GLP-1 drug development, novel drug delivery, pharmaceutical manufacturing and strategic licensing in a rapidly expanding therapeutic area.

Source: MannKind, Rose Pharma press release